Biopharmaceutical company focused on the development of immunotherapy to prevent breast cancer recurrence.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical firm, specializes in developing innovative cancer immunotherapies targeting breast cancer and other HER2/neu-expressing malignancies. The company’s flagship product, GP2, is an immunotherapy designed to prevent breast cancer recurrences in post-surgical patients, having successfully completed a Phase IIb clinical trial.
The company, originally named Norwell, Inc., rebranded to Greenwich LifeSciences, Inc. in March 2018. This name change reflects its renewed focus and commitment to advancing cancer treatment options. Incorporated in 2006, Greenwich LifeSciences has steadily progressed in the biopharmaceutical sector, leveraging cutting-edge research and clinical studies to combat cancer.
Headquartered in Stafford, Texas, Greenwich LifeSciences continues to build its portfolio of cancer therapies, aiming to address significant unmet medical needs. The firm’s strategic location and robust research initiatives position it at the forefront of immunotherapy development, with a dedicated team working towards breakthroughs in cancer care.